DekaBank Deutsche Girozentrale Cuts Stock Position in ImmunityBio, Inc. $IBRX

DekaBank Deutsche Girozentrale reduced its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 4.3% in the second quarter, Holdings Channel.com reports. The firm owned 196,200 shares of the company’s stock after selling 8,892 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in ImmunityBio were worth $525,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IBRX. Vanguard Group Inc. boosted its holdings in shares of ImmunityBio by 17.4% in the 1st quarter. Vanguard Group Inc. now owns 20,344,554 shares of the company’s stock worth $61,237,000 after purchasing an additional 3,016,325 shares in the last quarter. Citigroup Inc. boosted its holdings in ImmunityBio by 605.9% during the 1st quarter. Citigroup Inc. now owns 2,714,662 shares of the company’s stock valued at $8,171,000 after acquiring an additional 2,330,086 shares during the period. Nuveen LLC purchased a new stake in ImmunityBio during the 1st quarter valued at about $1,083,000. Plancorp LLC purchased a new stake in ImmunityBio during the 2nd quarter valued at about $717,000. Finally, Swiss National Bank boosted its holdings in ImmunityBio by 49.8% during the 1st quarter. Swiss National Bank now owns 410,400 shares of the company’s stock valued at $1,235,000 after acquiring an additional 136,400 shares during the period. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX opened at $2.47 on Monday. ImmunityBio, Inc. has a 52-week low of $1.83 and a 52-week high of $7.48. The firm has a market capitalization of $2.43 billion, a P/E ratio of -5.15 and a beta of 0.27. The stock has a 50 day moving average price of $2.48 and a 200-day moving average price of $2.60.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $26.43 million during the quarter, compared to the consensus estimate of $21.95 million. On average, equities analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on IBRX. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a report on Wednesday, September 10th. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Tuesday, October 14th. Finally, D. Boral Capital restated a “buy” rating and set a $24.00 target price on shares of ImmunityBio in a report on Monday, September 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.75.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.